GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). - Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; et al. (Journal of neurology, 2024)